Merck Serono files oral MS drug cladribine in the US
This article was originally published in Scrip
Executive Summary
Merck Serono has filed its oral DNA synthesis inhibitor Cladribine Tablets (cladribine) in the US for the treatment of relapsing-remitting multiple sclerosis (RRMS).